Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tamper-Resistance Could Allow New Opioid Formulations To Differentiate Themselves

Executive Summary

A claim for tamper-resistance rather than broad abuse-deterrence appears to be the immediate path forward for companies seeking to differentiate a new opioid product by its ability to impede recreational use.
Advertisement

Related Content

Opioid Abuse-Deterrent Labeling Claim Decision By FDA Could Come Soon
Abuse Reduction Claim In Opioid Label Will Be Difficult To Attain
Opioid Sponsors To Get Help Developing Abuse-Resistant Products From FDA, NIH
DEA Scheduling Delays Can Be Reduced With Early Studies, Frequent Sharing
Remoxy's Abuse Liability Study May Offer Clues On FDA's Upcoming Opioid Guidance
Private Grünenthal Aims For Leadership In Pain
Regulatory And Policy News, In Brief
Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?
FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads
FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads

Topics

Advertisement
UsernamePublicRestriction

Register

PS052788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel